Key Material For Diagnostic Agent Temporarily Stops Exporting To Japan
This article was originally published in PharmAsia News
Executive Summary
Due to a production halt caused by reactor trouble at Atomic Energy of Canada Ltd, molybdenum 99, a key material for cancer and vascular diagnostic agents, will not be exported to Japan temporarily. Japan Radioisotope Association May 26 notified medical facilities nationwide. The production halt is expected to last for more than one month. AECL accounts for over half of worldwide molybdenum 99 production. (Click here for more - Japanese language
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.